Lv71
4540 积分 2022-05-11 加入
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
24天前
已完结
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
1个月前
已完结
Drug development of MET inhibitors: targeting oncogene addiction and expedience
1个月前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
2个月前
已完结
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
2个月前
已完结
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
2个月前
已完结
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study
3个月前
已完结
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study
3个月前
已完结
KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP
3个月前
已完结
皖公网安备34019202002308
